Home/Pipeline/Not Specified (TCR Therapy)

Not Specified (TCR Therapy)

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

T-Cure Bioscience

About T-Cure Bioscience

T-Cure Bioscience is a private, clinical-stage biotech focused on TCR therapies for solid tumors. The company leverages its proprietary iSORT platform to identify and develop novel TCRs against cancer/testis antigens and other targets. With a pipeline in early clinical development, T-Cure aims to address the significant unmet need in solid tumor oncology, positioning itself in the competitive but high-potential cell therapy landscape. Leadership includes T cell expert and CEO Gang Zeng, PhD.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed